Latest Breaking News On - Lgans infant malabsorption treatment reduces complications in phase iii - Page 1 : comparemela.com

The Phase III study showed that ELGN-GI not only improved gastrointestinal (GI) function, but it also reduced life-threatening complications.

Noord hollandMiki olshanskyElgan pharmareleasedHans van goudoeverElgan pharmaUniversity of amsterdamIsrael headquartered elgan pharmareleasedProfessor hansLgans infant malabsorption treatment reduces complications in phase iii